First reported by Twitter / X
Oxford researchers develop statin muscle disorder risk calculator
New calculator reveals whether you should really worry about statin side effects
5d ago
Source
ScienceDailyNew calculator reveals whether you should really worry about statin side effectssciencedaily.comScientists at the University of Oxford have created a calculator that predicts a person's individual risk of serious muscle disorders from statin medications. Their analysis found that more than 98% of people who qualify for statins are at low risk for these rare complications, despite widespread concerns about side effects. The study also revealed that most eligible patients are not taking statins, potentially missing important protection against heart attacks and strokes.
You might also wanna read
Oxford researchers develop statin muscle disorder risk calculator
Researchers at the University of Oxford have developed a new risk calculator that estimates a person's likelihood of developing serious musc
Serious statin muscle side effects are rare for most people, new calculator shows
medicalxpress.com·6d ago

Study reveals molecular mechanism linking statins to muscle side effects via NLRP3 inflammasome and protein-prenylation pathway
This scientific research article investigates the molecular mechanisms behind statin-associated myopathy (muscle side effects). The study fi
Statin Initiation Linked to Reduced Frailty Risk in Older Adults, Study Finds
A study published in the European Heart Journal found that older adults who initiated statin therapy, including those with prefrailty at bas
Opinion: Statin Use May Pose Greater Diabetes Risk Than FDA Acknowledges
This opinion piece argues that the widespread use of statins for cholesterol reduction may lead to a significant increase in Type 2 diabetes
Clinical Trials Exclude High-Risk Patients, Underestimating Drug Harms
This research paper examines how clinical trials systematically exclude high-risk patients, leading to underestimation of drug harms and sid

Comments
Sign in to join the conversation.
No comments yet. Be the first.